TCR2 Therapeutics Analyst Ratings
TCR2 Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/05/2023 | 90.48% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 11/21/2022 | 1138.1% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 11/08/2022 | 90.48% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/19/2022 | 1233.33% | HC Wainwright & Co. | $19 → $14 | Maintains | Buy |
| 03/23/2022 | 185.71% | SVB Leerink | $7 → $3 | Maintains | Market Perform |
| 01/19/2022 | 376.19% | Goldman Sachs | $28 → $5 | Downgrades | Buy → Neutral |
| 01/13/2022 | 1709.52% | HC Wainwright & Co. | $25 → $19 | Maintains | Buy |
| 11/10/2021 | 566.67% | SVB Leerink | $8 → $7 | Maintains | Market Perform |
| 10/21/2021 | 661.9% | SVB Leerink | $18 → $8 | Downgrades | Outperform → Market Perform |
| 09/20/2021 | 2661.9% | Truist Securities | $40 → $29 | Maintains | Buy |
| 09/20/2021 | 2280.95% | HC Wainwright & Co. | $37 → $25 | Maintains | Buy |
| 09/17/2021 | 947.62% | Wedbush | $45 → $11 | Downgrades | Outperform → Neutral |
| 08/06/2021 | 2852.38% | SVB Leerink | $34 → $31 | Maintains | Outperform |
| 06/24/2021 | 2757.14% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 03/11/2021 | 3138.1% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 12/14/2020 | 3423.81% | HC Wainwright & Co. | $32 → $37 | Maintains | Buy |
| 11/30/2020 | 3519.05% | Roth Capital | $35 → $38 | Maintains | Buy |
| 08/21/2020 | — | Mizuho | Initiates Coverage On | → Buy | |
| 08/13/2020 | 3709.52% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 08/13/2020 | 2947.62% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/12/2020 | 2280.95% | SVB Leerink | $26 → $25 | Maintains | Outperform |
| 08/12/2020 | 3233.33% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 3233.33% | Roth Capital | $16 → $35 | Upgrades | Neutral → Buy |
| 07/27/2020 | 3042.86% | HC Wainwright & Co. | $19 → $33 | Maintains | Buy |
| 11/04/2019 | 1709.52% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 05/31/2019 | 1423.81% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 03/11/2019 | 2566.67% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 3423.81% | BMO Capital | → $37 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2852.38% | Jefferies | → $31 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/05/2023 | 90.48% | EF Hutton | → $2 | 開始承保 | →保留 |
| 11/21/2022 | 1138.1% | HC Wainwright公司 | $14 → $13 | 維護 | 買 |
| 11/08/2022 | 90.48% | SVB Leerink | $3 → $2 | 維護 | 市場表現 |
| 05/19/2022 | 1233.33% | HC Wainwright公司 | $19 → $14 | 維護 | 買 |
| 03/23/2022 | 185.71% | SVB Leerink | $7 → $3 | 維護 | 市場表現 |
| 01/19/2022 | 376.19% | 高盛 | $28 → $5 | 評級下調 | 購買→中性 |
| 01/13/2022 | 1709.52% | HC Wainwright公司 | $25 → $19 | 維護 | 買 |
| 11/10/2021 | 566.67% | SVB Leerink | $8 → $7 | 維護 | 市場表現 |
| 10/21/2021 | 661.9% | SVB Leerink | $18 → $8 | 評級下調 | 跑贏→市場表現 |
| 09/20/2021 | 2661.9% | Truist證券 | $40 → $29 | 維護 | 買 |
| 09/20/2021 | 2280.95% | HC Wainwright公司 | $37 → $25 | 維護 | 買 |
| 09/17/2021 | 947.62% | 韋德布什 | $45 → $11 | 評級下調 | 跑贏→中性 |
| 08/06/2021 | 2852.38% | SVB Leerink | $34 → $31 | 維護 | 跑贏大盤 |
| 06/24/2021 | 2757.14% | 高盛 | → $30 | 開始承保 | →購買 |
| 03/11/2021 | 3138.1% | SVB Leerink | $41 → $34 | 維護 | 跑贏大盤 |
| 12/14/2020 | 3423.81% | HC Wainwright公司 | $32 → $37 | 維護 | 買 |
| 11/30/2020 | 3519.05% | 羅斯資本 | $35 → $38 | 維護 | 買 |
| 08/21/2020 | — | 瑞穗 | 開始承保 | →購買 | |
| 08/13/2020 | 3709.52% | Truist證券 | → $40 | 開始承保 | →購買 |
| 08/13/2020 | 2947.62% | HC Wainwright公司 | $33 → $32 | 維護 | 買 |
| 08/12/2020 | 2280.95% | SVB Leerink | $26 → $25 | 維護 | 跑贏大盤 |
| 08/12/2020 | 3233.33% | 派珀·桑德勒 | → $35 | 開始承保 | →超重 |
| 07/27/2020 | 3233.33% | 羅斯資本 | $16 → $35 | 升級 | 中性→購買 |
| 07/27/2020 | 3042.86% | HC Wainwright公司 | $19 → $33 | 維護 | 買 |
| 11/04/2019 | 1709.52% | HC Wainwright公司 | → $19 | 開始承保 | →購買 |
| 05/31/2019 | 1423.81% | 羅斯資本 | → $16 | 開始承保 | →中性 |
| 03/11/2019 | 2566.67% | 韋德布什 | → $28 | 開始承保 | →跑贏大盤 |
| 03/11/2019 | 3423.81% | 蒙特利爾銀行資本 | → $37 | 開始承保 | →跑贏大盤 |
| 03/11/2019 | 2852.38% | 傑富瑞 | → $31 | 開始承保 | →購買 |
What is the target price for TCR2 Therapeutics (TCRR)?
TCR2治療(TCRR)的目標價格是多少？
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $2.00 expecting TCRR to rise to within 12 months (a possible 90.48% upside). 7 analyst firms have reported ratings in the last year.
EF Hutton於2023年1月5日報道了TCR2治療公司(納斯達克：TCRR)的最新目標價。這家分析公司將目標價定為2.00美元，預計TCRR將在12個月內升至(可能上漲90.48%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for TCR2 Therapeutics (TCRR)?
TCR2治療公司(TCRR)的最新分析師評級是什麼？
The latest analyst rating for TCR2 Therapeutics (NASDAQ: TCRR) was provided by EF Hutton, and TCR2 Therapeutics initiated their hold rating.
對TCR2治療公司(納斯達克代碼：TCRR)的最新分析師評級是由EF Hutton提供的，TCR2治療公司啟動了他們的持有評級。
When is the next analyst rating going to be posted or updated for TCR2 Therapeutics (TCRR)?
TCR2治療公司(TCRR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TCR2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TCR2 Therapeutics was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與TCR2治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。TCR2治療公司的上一次評級是在2023年1月5日提交的，所以你應該預計下一次評級將在2024年1月5日左右的某個時候提供。
Is the Analyst Rating TCR2 Therapeutics (TCRR) correct?
分析師對TCR2治療公司(TCRR)的評級正確嗎？
While ratings are subjective and will change, the latest TCR2 Therapeutics (TCRR) rating was a initiated with a price target of $0.00 to $2.00. The current price TCR2 Therapeutics (TCRR) is trading at is $1.05, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的TCR2治療(TCRR)評級是以0.00美元至2.00美元的目標價啟動的。目前TCR2治療公司(TCRR)的交易價格為1.05美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。